Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations 06 December
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical 19 November
